Background
Diarrhoea is a common complication seen in renal transplant recipients. Post-transplantation diarrhoea may result from infectious agents, drug-specific effects or metabolic conditions. Although infections are the major cause of diarrhoea after transplantation, almost a quarter of the cases are related to medication. Approximately 50% of the drug-induced diarrhoea is caused by mycophenolate mofetil (MMF) [1] . MMF is a commonly used immunosuppressive agent that can induce ulcerating colitis [2, 3] . MMF-induced ulcerating colitis is a diagnosis by exclusion. The pathological diagnosis is difficult because of the similarities with other causes of diarrhoea such as inflammatory bowel disease [4] . Although MMF-induced colitis usually resolves after dose reduction or cessation of MMF, persistent cases have been reported [5] . We present a case in which MMF-induced ulcerating colitis persisted after withdrawal of MMF but was successfully treated with tumour necrosis factor-alpha (TNF-α) inhibition.
Case report
A 65-year-old female patient presented with a 1-week history of watery non-bloody diarrhoea, with weight loss and abdominal cramps. She passed ∼10 stools a day. Her medical history comprised a kidney transplantation 6 years earlier because of end-stage renal failure due to autosomal dominant polycystic kidney disease. The medication comprised tacrolimus 4 mg b.i.d. with MMF 500 mg b.i.d. and had not been changed recently. Physical examination revealed a temperature of 37.2°C, a blood pressure of 129/ 70 mmHg and a heart rate of 72 b.p.m. The abdomen was tender, with vivid bowel sounds. No enlarged lymph nodes were found. Laboratory investigation showed a leucocyte count of 9.9 × 10 9 /L, a C-reactive protein (CRP) of 66 mg/L and a serum creatinine level of 82 μmol/L. Stool cultures and examination for parasites were repeatedly negative. Cytomegalovirus (CMV) was excluded by quantitative polymerase chain reaction in plasma.
With the working hypothesis MMF-induced colitis, MMF was switched to prednisone 30 mg per os once daily. Because diarrhoea persisted for 2 weeks after withdrawal of MMF, a colonoscopy was performed that showed linear ulceration throughout the colon ( Figure 1A ). The terminal ileum showed no abnormalities. Histological examination revealed extensive ulceration with severe transmural mixed-cellular infiltration without granulomata ( Figure 1B ). Immunohistochemical staining for CMV was negative.
Because of a possible causative role, tacrolimus was also withdrawn, and 25 mg prednisolone was given intravenously b.i.d. as the sole immunosuppressive agent. As the clinical condition did not improve in the next 2 weeks, a second colonoscopy was performed, which showed no improvement.
Because of persistent non-infectious colitis 8 weeks after discontinuing MMF and 2-week high-dose steroid treatment, we decided to treat our patient with infliximab (5 mg/kg). Within 72 h, after a single infusion of infliximab, the stool frequency dropped from 10 to 4 times a day. Her appetite increased, and the abdominal cramps diminished. The CRP decreased to 3 mg/L, whereas serum creatinine remained unchanged (81 μmol/L). The prednisolone dose was tapered, and the patient was discharged 14 days later. The immunosuppressive regimen was finally changed to azathioprine 2 mg/kg once daily and prednisone 10 mg once daily.
Discussion
MMF is a pro-drug that is metabolized in the liver into the active compound mycophenolic acid (MPA). MPA is a reversible inhibitor of inosine monophosphate dehydrogenase, the rate-limiting enzyme in purine synthesis in lymphocytes. By inhibiting the proliferation of lymphocytes, MPA exerts its immunosuppressive action [6] . However, MPA also decreases the proliferation of enterocytes. MPA is further degraded by the liver to acyl gluconoride (AC) which stimulates mononuclear cells to release TNF-α. TNF-α plays a central role in the pathogenesis of mucosal inflammation. TNF-α causes disruption of the epithelial barrier, induces apoptosis and secretion of chemokines in epithelial cells, activates endothelial cells and inflammatory cells, and stimulates the production of matrix metalloproteinases [7] [8] [9] . This TNF-α-mediated inflammatory damage combined with reduced intestinal regeneration is the proposed mechanism of MMF-induced colitis.
In most cases, MMF dose reduction or withdrawal is sufficient to reverse the ulcerative colitis. However, in our case, the diarrhoea persisted despite discontinuing MMF and even after anti-inflammatory treatment using high-dose prednisone. Because the role of TNF-α in MMF-induced colitis and the histopathologic resemblance of MMF-induced colitis to Crohn's colitis, we decided to treat our patient with infliximab. Infliximab is a chimeric IgG1 monoclonal antibody which neutralizes the biological activity of TNF-α and causes apoptosis of TNF-α effector cells [9, 10] .
The rapid clinical response to infliximab suggests that TNF-α plays a crucial role in both the initiation and the maintenance of MMF-induced colitis.
After resolution of the MMF-induced ulcerating colitis, the patient was switched to azathioprine. It should be noted that the role of MMF as a preferred immunosuppressive agent to azathioprine in renal transplantation has recently been questioned by Cravedi et al. [11] . Indeed, the benefits of MMF over azathioprine have not been proven convincingly, especially in the light of higher cost and the unfavourable adverse event profile of the former drug.
Although our working hypothesis was MMF-induced colitis, we cannot completely rule out Crohn's disease. However, it is uncommon for Crohn's disease to start at age 65, without involvement of the small bowel and without granulomata in repeated biopsies. Furthermore, the occurrence of Crohn's disease despite immunosuppressive therapy and lack of clinical response to treatment with high-dose steroids are also atypical, favouring the diagnosis MMF-induced colitis.
To our knowledge, we here present the first case of persistent MMF-induced colitis that is successfully treated with infliximab. The rapid resolution of the diarrhoea in response to infliximab suggests that TNF-α is not only involved in the initiation but also in the maintenance of MMF-induced colitis. It should be stressed that infliximab is an expensive drug that potentially has serious side effects, and our observation is limited to only one case. However, infliximab might be an interesting new therapeutic option for the treatment of persistent MMF-induced colitis.
